Sri Kosaraju is the former chief executive officer at Inscripta, and currently serves as audit chair and board member at 10x Genomics, supporting advancements in life science technology. He also sits on the board at Manus Bio, contributing to the acceleration of biologically produced alternatives.
Previously he was a board member at Nevro until its acquisition by Globus. He also served as president and chief financial officer at Penumbra, Inc., and managing director at J.P. Morgan, where he led the Healthcare and TMT Equity Capital Markets divisions.
Kosaraju earned a bachelor’s degree in mechanical engineering from the Massachusetts Institute of Technology.
